The Institute of Cancer Research- It is one of The world’s most influential cancer research institute is . It gives intellectual instructions and trains the next generation of cancer researchers and clinicians and also to make discoveries that defeat cancer. They research on differences between cancer. The Institute of Cancer Research has ranked first in Times Higher Education League table of universities research from Research Excellence Frame Work. Research Excellence Frame Work is the leading academic institution in UK. The Institute of Cancer Research (ICR) was founded in 1909 and it joined the University of London in 2003 as a research department of Royal Marsden Hospital. It has been responsible for a number of breakthrough discoveries. It is affiliated to University of London. The ICR provides both postgraduate degree programme and research degrees and currently has around 340 students. ICR is the largest comprehensive cancer center in Europe including the Royal Marsden Hospital. The ICR receives its external grant funding from the government body the Higher Education Funding Council for England and from charities including the Cancer Research UK, Wellcome Trust, Breakthrough Breast Cancer and Leukaemia and Lymphoma Research. The ICR also runs a number of campaigns and fundraising appeals which helps to support a variety of cancer research projects. The ICR continues it’s research focused into three main research themes: Genetic Epidemiology, Molecular Pathology and Therapeutic development These areas of research are essential for the development of personalized cancer medicine. The ICR has started work on a £20 million Centre for Cancer Imaging that will bring experts together in a range of different imaging techniques who will work together developing better cancer diagnostic and treatment techniques. Scientist at the ICR were serving in the development of one of the world’s most widely used anti-cancer drugs. During 1980’s, scientists of ICR for the treatment of colon and other cancers, developed a drug active. In 1994 an ICR team was led by Michael Stratton and he discovered the BRCA2 gene, which was been linked to breast cancer, prostate cancer and ovarian cancer. In june 2009 “The phase 1 trial” of olaparib was found that tumors will shrank for more than half of patients with BRCA1 and BRCA2 mutations and moreover it is believed that the drug may also be useful in other patients whose cancer it is linked to an error in their DNA repair pathway. In 1990 Chester Beatty Laboratory extended and redeveloped to incorporate the Breakthrough Breast Cancer Research Center, which was opened by HRH The Prince of Wales. In the 5 years from 2000 to 2005, the ICR developed on average two drug development candidates per year. In laboratory experiments, ICR scientists also found that the drug reduced the growth of brain tumor, it decreased the growth of ovarian tumors and in other studies, it was active against cell lines derived from other human cancers.
The following is the list of proceedings by scholars from The Institute Of Cancer Research that are published in OMICS International journals and conferences.